Celcuity (NASDAQ:CELC) Stock Gets Price Target Cut from HC Wainwright

Celcuity (NASDAQ:CELC) had its target price cut by HC Wainwright from $155.00 to $150.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also recently weighed in on the company. Wall Street Zen cut Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Zacks Research downgraded shares of Celcuity from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Royal Bank Of Canada lowered shares of Celcuity to a “neutral” rating in a research note on Wednesday, October 28th. Guggenheim initiated coverage on shares of Celcuity in a research note on Friday, November 6th. They issued a “buy” rating and a $169.00 target price for the company. Finally, Needham & Company LLC lowered their target price on shares of Celcuity from $140.00 to $134.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Celcuity currently has a consensus rating of “Moderate Buy” and an average target price of $151.79.

Celcuity Stock Down 4.1%

Shares of Celcuity stock opened at $64.32 on Monday. Celcuity has a 52 week low of $53.54 and a 52 week high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 14.62 and a quick ratio of 8.93. The business has a 50 day moving average price of $73.75 and a 200-day moving average price of $98.74.

Celcuity (NASDAQ:CELC) last announced its earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.51) by $0.30. Equities research analysts predict that Celcuity will post -5.01 earnings per share for the current year.

Institutional Investors Weigh In On Celcuity

Large investors have recently made changes to their positions in the business. Teachers Retirement System of The State of Kentucky raised its stake in shares of Celcuity by 39.9% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 17,729 shares of the company’s stock worth $1,410,000 after purchasing an additional 5,053 shares during the period. ACT Capital Partners L.P. purchased a new position in shares of Celcuity in the 3rd quarter worth about $4,664,000. Nan Fung Trinity HK Ltd. grew its position in Celcuity by 33.4% during the third quarter. Nan Fung Trinity HK Ltd. now owns 103,775 shares of the company’s stock valued at $8,252,000 after buying an additional 25,975 shares during the period. Pictet Asset Management Holding SA grew its position in Celcuity by 10,659.7% during the third quarter. Pictet Asset Management Holding SA now owns 291,049 shares of the company’s stock valued at $23,144,000 after buying an additional 288,344 shares during the period. Finally, Integrity Alliance LLC. grew its position in Celcuity by 2.2% during the third quarter. Integrity Alliance LLC. now owns 11,868 shares of the company’s stock valued at $944,000 after buying an additional 250 shares during the period. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.